Stock VELO VELOXIS PHARMACEUTICALS A/S
Add to a list
To use this feature you must be a member
Log inSign up

MarketScreener Editorial Features Veloxis Pharmaceuticals A/S

Equities

VELO

DK0060048148

Delayed Nasdaq Copenhagen
Other stock markets
 		5-day change 1st Jan Change
- DKK -.--% Intraday chart for Veloxis Pharmaceuticals A/S -.--% -0.50%
2022 Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) CI
2021 Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA. CI

MarketScreener Editorial Features

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VELO Stock
  4. News Veloxis Pharmaceuticals A/S
  5. MarketScreener Editorial Features